N-Formyl Peptide 수용체 2 : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

N-Formyl Peptide 수용체 2를 표적으로 하는 약제의 적응증·개발 단계·작용기전·투여 경로·분자 종류별 분석, 약제의 약리작용, 지금까지의 연구개발 동향, 최신 뉴스와 발표, 약제 개발에 참여하고 있는 주요 기업 개요, 휴지 상태/중지된 프로젝트 등의 정보를 전해드립니다.

서론

• 조사 범위

N-Formyl Peptide 수용체 2 개요

치료제 개발

N-Formyl Peptide 수용체 2 : 개발중인 제품 - 개발 단계별

N-Formyl Peptide 수용체 2 : 개발중인 제품 - 치료 범위별

N-Formyl Peptide 수용체 2 : 개발중인 제품 - 적응증별

N-Formyl Peptide 수용체 2 : 파이프라인 제품 개요

• 초기 단계 제품

N-Formyl Peptide 수용체 2 : 기업에서 개발중인 제품

N-Formyl Peptide 수용체 2 : 대학/연구기관에서 개발중인 제품

N-Formyl Peptide 수용체 2 : 치료제 평가

• 단독요법/병용요법 제품별
• 작용기전별
• 분자 종류별

N-Formyl Peptide 수용체 2 치료제 개발에 참여하고 있는 기업

• Bristol-Myers Squibb Company
• CohBar, Inc.
• Polyphor Ltd.

치료제 개요

N-Formyl Peptide 수용체 2 : 휴지 상태인 프로젝트

N-Formyl Peptide 수용체 2 : 개발이 중지된 제품

N-Formyl Peptide 수용체 2 : 주요 뉴스와 프레스 릴리스

부록

List of Tables

• Number of Products under Development by Stage of Development, H2 2019
• Number of Products under Development by Therapy Areas, H2 2019
• Number of Products under Development by Indication, H2 2019
• Number of Products under Development by Companies, H2 2019
• Products under Development by Companies, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Stage and Route of Administration, H2 2019
• Number of Products by Stage and Molecule Type, H2 2019
• Pipeline by Bristol-Myers Squibb Co, H2 2019
• Pipeline by CohBar Inc, H2 2019
• Pipeline by Limulus Therapeutics Pty Ltd, H2 2019
• Pipeline by NovaCell Technology Inc, H2 2019
• Pipeline by ResoTher Pharma ApS, H2 2019
• Pipeline by Trio Medicines Ltd, H2 2019
• Dormant Projects, H2 2019
• Discontinued Products, H2 2019

List of Figures

• Number of Products under Development by Stage of Development, H2 2019
• Number of Products under Development by Therapy Areas, H2 2019
• Number of Products under Development by Top 10 Indications, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Routes of Administration, H2 2019
• Number of Products by Stage and Routes of Administration, H2 2019
• Number of Products by Molecule Types, H2 2019
• Number of Products by Stage and Molecule Types, H2 2019

Summary

According to the recently published report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019'; N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) pipeline Target constitutes close to 8 molecules.

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - N-formyl peptide receptor 2 (FPR2) is a G-protein coupled receptor (GPCR) encoded by the FPR2 gene and is activated to regulate cell function by binding to a wide variety of ligands like N-Formylmethionine-containing oligopeptides such as N-Formylmethionine-leucyl-phenylalanine (FMLP), polyunsaturated fatty acid metabolite of arachidonic acid, lipoxin A4 (LXA4). FPR2 mediates responses to a wide range of polypeptides and proteins which may serve to promote inflammation.

The report 'N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019' outlays comprehensive information on the N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I and Preclinical stages are 2 and 6 respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Immunology, Dermatology, Gastrointestinal, Infectious Disease, Metabolic Disorders and Oncology which include indications Inflammation, Alzheimer's Disease, Atherosclerosis, Atopic Dermatitis (Atopic Eczema), Cardiovascular Disease, Congestive Heart Failure (Heart Failure), Crohn's Disease (Regional Enteritis), Fungal Infections, Ischemia Reperfusion Injury, Ischemic Stroke, Metastatic Cancer, Multiple Sclerosis, Myocardial Infarction, Myocardial Ischemia, Staphylococcus aureus Infections and Type 2 Diabetes.

Scope

• The report provides a snapshot of the global therapeutic landscape for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
• The report reviews N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics and enlists all their major and minor projects
• The report assesses N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

• Introduction
• Global Markets Direct Report Coverage
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Overview
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Companies Involved in Therapeutics Development
• Bristol-Myers Squibb Co
• CohBar Inc
• Limulus Therapeutics Pty Ltd
• NovaCell Technology Inc
• ResoTher Pharma ApS
• Trio Medicines Ltd
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Drug Profiles
• Humanin - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• NCP-112 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• NCP-70X - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• RTP-025 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• RTP-026 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Small Molecule to Agonize FPR-2 for Heart Failure and Inflammation - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• TR-8 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Dormant Products
• N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Discontinued Products
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer